Marker Therapeutics (FRA:GX1) Cyclically Adjusted FCF per Share: €-4.29 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:GX1 Marker Therapeutics Inc FRA:GX1
33 GF Score
Price €0.89
! 1 Warning Sign
View Full Analysis

What is Marker Therapeutics Cyclically Adjusted FCF per Share?

Marker Therapeutics FRA:GX1 -4.32% 33 Cyclically Adjusted FCF per Share is €-4.29 as of Mar. 2026. GuruFocus rates FRA:GX1 with a GF Score™ of 33/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Marker Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.063. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-4.29 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 33.50% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 44.60% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 33.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Marker Therapeutics was 53.80% per year. The lowest was 7.30% per year. And the median was 14.65% per year.

As of today (2026-07-30), Marker Therapeutics's current stock price is €0.885. Marker Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-4.29. Marker Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Marker Therapeutics  (FRA:GX1) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Marker Therapeutics Cyclically Adjusted FCF per Share Related Terms


Marker Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Marker Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marker Therapeutics Cyclically Adjusted FCF per Share Chart

Marker Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -49.04 -16.32 -4.75 -7.54 -4.64

Marker Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.71 -4.71 -4.50 -4.64 -4.29

FRA:GX1 vs NCEL, HOWL, CVM: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Marker Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marker Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marker Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Marker Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


FRA:GX1
33GF Score
Marker Therapeutics Inc FRA:GX1
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Marker Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Marker Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.063/330.2130*330.2130
=-0.063

Current CPI (Mar. 2026) = 330.2130.

Marker Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -2.667 241.018 -3.654
201609 -2.413 241.428 -3.300
201612 -1.873 241.432 -2.562
201703 -2.134 243.801 -2.890
201706 -2.087 244.955 -2.813
201709 -1.662 246.819 -2.224
201712 -1.981 246.524 -2.654
201803 -1.792 249.554 -2.371
201806 -1.735 251.989 -2.274
201809 -2.229 252.439 -2.916
201812 -1.192 251.233 -1.567
201903 -0.799 254.202 -1.038
201906 -0.829 256.143 -1.069
201909 -1.138 256.759 -1.464
201912 -0.900 256.974 -1.157
202003 -0.825 258.115 -1.055
202006 -1.550 257.797 -1.985
202009 -1.332 260.280 -1.690
202012 -1.623 260.474 -2.058
202103 -1.413 264.877 -1.762
202106 -0.718 271.696 -0.873
202109 -0.871 274.310 -1.049
202112 -0.554 278.802 -0.656
202203 -1.604 287.504 -1.842
202206 -0.090 296.311 -0.100
202209 -0.924 296.808 -1.028
202212 -0.711 296.797 -0.791
202303 -0.631 301.836 -0.690
202306 -0.740 305.109 -0.801
202309 -0.120 307.789 -0.129
202312 -0.244 306.746 -0.263
202403 -0.397 312.332 -0.420
202406 -0.372 314.175 -0.391
202409 0.121 315.301 0.127
202412 -0.489 315.605 -0.512
202503 -0.458 319.799 -0.473
202506 -0.117 322.561 -0.120
202509 -0.139 324.800 -0.141
202512 -0.084 324.054 -0.086
202603 -0.063 330.213 -0.063

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-4.29 mean?
Marker Therapeutics (FRA:GX1) has a Cyclically Adjusted FCF per Share of €-4.29 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Marker Therapeutics and its competitors.
Is Marker Therapeutics' Cyclically Adjusted FCF per Share too high?
Marker Therapeutics' current Cyclically Adjusted FCF per Share is €-4.29. Overall, Marker Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Marker Therapeutics' Cyclically Adjusted FCF per Share compare to NCEL and HOWL?
Marker Therapeutics' Cyclically Adjusted FCF per Share of €-4.29 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Marker Therapeutics and its competitors. Marker Therapeutics's current Cyclically Adjusted FCF per Share is €-4.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marker Therapeutics stock overvalued right now?
Marker Therapeutics (FRA:GX1) has a current Cyclically Adjusted FCF per Share of €-4.29. The current Cyclically Adjusted FCF per Share is €-4.29. Marker Therapeutics' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Marker Therapeutics (FRA:GX1), the current Cyclically Adjusted FCF per Share is €-4.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Marker Therapeutics Business Description

Other Exchanges MRKR:USA
Address 2450 Holcombe Boulevard, TMC Partners Office 1.311, Houston, TX, USA, 77021
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
33GF Score

Get the complete analysis for FRA:GX1

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.89
Price